Evaluate Vantage Homepage
AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
Daiichi torches Esperion’s Nexletol milestone promises
Despite assurances by Esperion, Daiichi is refusing to pay up after the Clear Outcomes disappointment.
Lazertinib and Tagrisso go head to head
A key test of J&J’s targeted agent approaches, but Astra has a trick up its sleeve that could render this readout irrelevant.
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Altimmune aims to build Momentum in obesity
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
Novo sows the seeds for a new heart failure approach
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.
Spybiotech seeks new vaccines
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.
Biohaven looks to seize a new opportunity
The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.